Skip to Content

Join the 'Soliqua' group to help and get support from people like you.

Soliqua News

Dealing With Diabetes Distress

Posted 16 Feb 2017 by Drugs.com

THURSDAY, Feb. 16, 2017 – People with diabetes have to think about their condition and make treatment decisions constantly – and all that extra work and worry can lead to psychological distress at times. "Diabetes distress" isn't the same as depression, however, diabetes experts note. It's a condition unique to the 24/7 demands that come with diabetes, particularly for people dependent on insulin. "The day you develop diabetes, it's like the universe just handed you a new full-time job that you have to do in addition to whatever else you're doing. It's a special job that has a big impact on the rest of your life. There's no pay and no vacation," said William Polonsky, president of the Behavioral Diabetes Institute in San Diego. Alicia McAuliffe-Fogarty, vice president of lifestyle management at the American Diabetes Association, put it this way: "Diabetes distress is the extra burden ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Glyburide, Invokana, Lantus Solostar, Levemir, Pre-Diabetes, Actos, Glimepiride, Novolin R, Amaryl

Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and lixisenatide) for the Treatment of Adults with Type 2 Diabetes

Posted 22 Nov 2016 by Drugs.com

PARIS, Nov. 21, 2016 /PRNewswire-USNewswire/ – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection) 100 Units/mL & 33 mcg/mL for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide*. Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection, studied in a Phase 3 program of more than 1,900 patients. In an insulin intensification study, Soliqua 100/33 showed better HbA1c (average blood sugar over time) lowering versus Lantus with a majority of the 736 patients (55% vs. 30%) achieving the American Diabetes Association target of less than 7% at 30 weeks. Patients treated with Soliqua 100/33 experienced similar rates of documented ... Read more

Related support groups: Diabetes, Type 2, Lantus, Insulin Glargine, Soliqua, Adlyxin, Insulin Glargine/lixisenatide, Lixisenatide

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Soliqua Patient Information at Drugs.com